Japanese government approves two laser systems to treat common Asian skin lesions.TOKYO--(BUSINESS WIRE)--Nov. 14, 1996-- Ministry of Health and National Health Program Clear Candela's ALEXLAZR and PLTL PLTL - Propositional Linear Temporal Logic Pigmented Lesion/TATULAZR For Nevus of Ota nevus of Ota A bluish or gray-brown macular lesion of the periorbital skin innervated by the 1st and 2nd branches of trigeminal nerve Treatment Selective photothermolysis with a Q-switched ruby laser, surgical removal, skin grafting, , Other Conditions Candela Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CLZR) announced today that the Japanese government has cleared two powerful new laser systems which gently but effectively treat skin conditions native to the Asian population -- brown pigmented skin lesions such as Nevus of Ota, Mongolian spot, and traumatic pigmentation. The devices, both using Candela's Alexandrite alexandrite type of chrysoberyl typifying undying devotion. [Gem Symbolism: Jobes, 67] See : Loyalty Laser technology, are known as the ALEXLAZR(TM) and the PLTL Pigmented Lesion/TATULAZR(TM). The laser systems have received marketing approval from Japan's Ministry of Health (MOH See modem on hold. ) and obtained reimbursement approval from the National Health Insurance of Japan, it was announced today by Gerard E. Puorro, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Candela. In the United States, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. had already cleared the ALEXLAZR and the PLTL for treating brown spots of the skin caused by sun exposure and sun damage, brown pigmented skin lesions such as Nevus of Ota, Mongolian spot, and traumatic pigmentation, and the removal of unwanted tattoos. The Japanese decisions are significant for Candela, since a large percentage of the company's revenue is generated from the international marketplace, especially from Asian customers, Mr. Puorro said. Toshio Mori, president of Candela's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in Japan, said, "We are delighted with the decisions regarding the key Japanese treatment and reimbursement issues. These decisions will expand our market substantially by adding 2,000 public hospital sites here in Japan, enabling many more people to receive the treatment they want and need." Candela Corporation develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons and personal care practitioners to treat selected cosmetic and medical problems using lasers, cryosurgery cryosurgery (krī`ōsr'jərē), bloodless surgical technique using a supercooled probe to destroy diseased or superfluous tissue. and other proven technologies. In addition, the company is applying its capabilities and experience with skin care and related problems to develop a network of company-owned skin care centers and spas. Founded near Boston in 1970 as Candela Laser Corporation, Candela markets and services its products in over 40 countries from offices in the United States, Europe and the Far East. For more information about Candela, visit the company's Web site at http://www.clzr.com. This press release includes certain forward-looking statements. Any such statements are subject to risks that could cause the actual results to vary materially, including negative developments relating to unforeseen order cancellations or push-outs, Candela's strategic relationships, the impact of intense competition, and changes in the laser industry. CONTACT: Joanne Kelley 508/358-7400 x488, Candela Corporation Stuart Pearlman 212/370-4940, Stuart Pearlman & Co. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion